All Stories

  1. IS PYLERA® STILL EFFECTIVE AND SAFE IN PATIENTS INFECTED BY HELICOBACTER PYLORI? A SIX-YEARS, MULTICENTRE, REAL LIFE STUDY

    Article • Digestive Diseases, October 2026, Karger Publishers

    Prof. Antonio Tursi

  2. The DICA endoscopic score and the CODA clinical score may predict the severity of acute diverticulitis and the risk of hospitalisation: results from an international multicentre prospective cohort study

    Article • Techniques in Coloproctology, May 2026, Springer Science + Business Media

    Prof. Antonio Tursi

  3. An inverse probability of treatment weighted comparison between vedolizumab, ustekinumab, and tofacitinib in anti-TNF-experienced ulcerative colitis patients

    Article • Therapeutic Advances in Gastroenterology, May 2026, SAGE Publications

    Prof. Antonio Tursi

  4. Analysis of possible baseline and treatment-course factors associated with non-remission in patients with Crohn’s disease treated with ustekinumab: a retrospective real-life analysis

    Article • Pharmacological Reports, March 2026, Springer Science + Business Media

    Prof. Antonio Tursi

  5. Optimal use of rifaximin in diverticular disease of the colon: use less for use better

    Article • Gut, March 2026, BMJ

    Prof. Antonio Tursi

  6. Concomitant 5‐Aminosalicylic Acid Does Not Affect the Efficacy of Janus Kinase Inhibitors in Ulcerative Colitis

    Article • Clinical Pharmacology & Therapeutics, March 2026, Wiley

    Prof. Antonio Tursi

  7. Evaluation of the Effect of a Cranberry Formulation in Reducing the Inflammatory State and Improving the Management of Symptoms in Patients with Symptomatic Uncomplicated Diverticular Disease: A Prospective, Open-Label, Single-Arm, Multi-Center, Pilot ...

    Article • Pharmaceutics, December 2025, MDPI AG

    Prof. Antonio Tursi

  8. Global guidelines on diverticular disease of the colon: the Fiesole Consensus report

    Article • Gut, December 2025, BMJ

    Prof. Antonio Tursi

  9. Upadacitinib’s Effectiveness and Safety as a Second- or Third-Line Therapy in Patients with Ulcerative Colitis: Data from a Real-World Study

    Article • Journal of Clinical Medicine, November 2025, MDPI AG

    Prof. Antonio Tursi

  10. Impact of Diet on Gut Microbiota in Diverticular Disease of the Colon: An Exploratory Retrospective Study

    Article • Microorganisms, October 2025, MDPI AG

    Prof. Antonio Tursi

  11. Sex-Specific Real-Life Profiling in Vedolizumab, Ustekinumab, and Tofacitinib Effectiveness in Ulcerative Colitis

    Article • Journal of Clinical Medicine, October 2025, MDPI AG

    Prof. Antonio Tursi

  12. Lactobacillus Paracasei CNCM I 1572 is Better than Placebo in Preventing Acute Diverticulitis Occurrence (Revised Manuscript 661a120f-b910-4133-ab7e-4bd3e1713c96)

    Article • Probiotics and Antimicrobial Proteins, October 2025, Springer Science + Business Media

    Prof. Antonio Tursi

  13. Management of Post-Colonoscopy Syndrome with a Nutraceutical Intervention Based on Hericium erinaceus: A Retrospective Two-Arm Multicentre Analysis

    Article • Nutrients, October 2025, MDPI AG

    Prof. Antonio Tursi

  14. Filgotinib effectiveness and safety as second or third-line therapy in patients with ulcerative colitis: data from a real-world study

    Article • Intestinal Research, September 2025, Korean Association for the Study of Intestinal Diseases (KAMJE)

    Prof. Antonio Tursi

  15. Efficacy of a Preparation based on Symbiotic Association Between Inulin, FOS, L. rhamnosus GG, Bromelin, Boswellia, Vitamin D3, Quercetin andL-tryptophan in Mild-to-Moderate Ulcerative Colitis: A Pilot Retrospective Multicenter Study

    Article • Reviews on Recent Clinical Trials, August 2025, Bentham Science Publishers

    Prof. Antonio Tursi

  16. Complicated diverticulitis: medical management or segmental resection?

    Article • Expert Review of Gastroenterology & Hepatology, June 2025, Taylor & Francis

    Prof. Antonio Tursi

  17. STW 5-II FOR TREATMENT OF FUNCTIONAL GASTROINTESTINAL DISORDERS: MECHANISM AND CLINICAL EFFICACY

    Article • Digestive Diseases, February 2025, Karger Publishers

    Prof. Antonio Tursi

  18. The role of gut microbiota in the pathogenesis of diverticular disease: where are we now?

    Article • Genome Medicine, December 2024, Springer Science + Business Media

    Prof. Antonio Tursi

  19. Long-Term Effectiveness and Safety of Ustekinumab in Crohn’s Disease: Results from a Large Real-Life Cohort Study

    Article • Journal of Clinical Medicine, November 2024, MDPI AG

    Prof. Antonio Tursi

  20. Editorial: Effectiveness and safety of ustekinumab in ulcerative colitis—Where we are now

    Article • Alimentary Pharmacology & Therapeutics, October 2024, Wiley

    Prof. Antonio Tursi

  21. Enhancing Oral 5-ASA Effectiveness in Mild-to-Moderate Ulcerative Colitis through an H. erinaceus-Based Nutraceutical Add-on Multi-Compound: The “HERICIUM-UC” Two-Arm Multicentre Retrospective Study

    Article • Pharmaceutics, August 2024, MDPI AG

    Prof. Antonio Tursi

  22. Bowel movement alterations predict the severity of diverticular disease and the risk of acute diverticulitis: a prospective, international st

    Article • Intestinal Research, August 2024, Korean Association for the Study of Intestinal Diseases (KAMJE)

    Prof. Antonio Tursi, Professor Gabrio Bassotti

  23. Impact of a Symbiotic Mixture on Moderate-to-severe Diverticular Disease of the Colon

    Article • Reviews on Recent Clinical Trials, July 2024, Bentham Science Publishers

    Prof. Antonio Tursi

  24. Ustekinumab in the Treatment of Inflammatory Bowel Diseases: Evolving Paradigms

    Article • Journal of Clinical Medicine, March 2024, MDPI AG

    Prof. Antonio Tursi

  25. Clinical use of biologics for Crohn’s disease in adults: lessons learned from real-world studies

    Article • Expert Opinion on Biological Therapy, February 2024, Taylor & Francis

    Prof. Antonio Tursi

  26. Ustekinumab safety and effectiveness in patients with ulcerative colitis: results from a large real-life study

    Article • Expert Opinion on Biological Therapy, January 2024, Taylor & Francis

    Prof. Antonio Tursi

  27. Ustekinumab in the Treatment of Inflammatory Bowel Diseases: Evolving Paradigms

    Article • January 2024, MDPI AG

    Prof. Antonio Tursi

  28. Diverticular Inflammation and Complication Assessment classification, CODA score and fecal calprotectin in clinical assessment of patients with diverticular disease: A decision curve analysis

    Article • United European Gastroenterology Journal, August 2023, Wiley

    Prof. Antonio Tursi, Professor Gabrio Bassotti

  29. Prevalence and Natural History of Segmental Colitis Associated With Diverticulosis

    Article • The American Journal of Gastroenterology, July 2023, Wolters Kluwer Health

    Prof. Antonio Tursi

  30. Ulcerative Colitis After Complicated Diverticulitis

    Article • ACG Case Reports Journal, March 2023, Wolters Kluwer Health

    Prof. Antonio Tursi

  31. Real-world efficacy and safety of vedolizumab in managing ulcerative colitis versus Crohn’s disease: results from an Italian multicenter study

    Article • Expert Opinion on Biological Therapy, February 2023, Taylor & Francis

    Prof. Antonio Tursi

  32. Appropriateness of Proton Pump Inhibitor Prescription Evaluated by Using Serological Markers

    Article • International Journal of Molecular Sciences, January 2023, MDPI AG

    Prof. Antonio Tursi

  33. Microbiota Composition in Diverticular Disease: Implications for Therapy

    Article • International Journal of Molecular Sciences, November 2022, MDPI AG

    Prof. Antonio Tursi

  34. When to Perform a Colonoscopy in Diverticular Disease and Why: A Personalized Approach

    Article • Journal of Personalized Medicine, October 2022, MDPI AG

    Prof. Antonio Tursi

  35. Adalimumab Biosimilar GP2017 versus Adalimumab Originator in Treating Patients with Inflammatory Bowel Diseases: A Real-Life, Multicenter, Observational Study

    Article • Biomedicines, July 2022, MDPI AG

    Prof. Antonio Tursi

  36. Comparison of Performances of Adalimumab Biosimilars SB5, APB501, GP2017, and MSB11022 in Treating Patients with Inflammatory Bowel Diseases: A Real-Life, Multicenter, Observational Study

    Article • Inflammatory Bowel Diseases, May 2022, Oxford University Press (OUP)

    Prof. Antonio Tursi

  37. Impact of SARS-CoV-2 Infection on the Course of Inflammatory Bowel Disease in Patients Treated with Biological Therapeutic Agents: A Case-Control Study

    Article • Biomedicines, April 2022, MDPI AG

    Prof. Antonio Tursi, Marcello Covino

  38. Diverticular Inflammation and Complication Assessment (DICA) Classification

    Article • January 2022, Springer Science + Business Media

    Prof. Antonio Tursi

  39. Comparison of Performances of Infliximab Biosimilars CT-P13 Versus SB2 in the Treatment of Inflammatory Bowel Diseases: A Real-Life Multicenter, Observational Study in Italy

    Article • Expert Opinion on Biological Therapy, December 2021, Taylor & Francis

    Prof. Antonio Tursi

  40. COVID-19 as a Trigger for De Novo Crohn’s Disease

    Article • Inflammatory Bowel Diseases, November 2021, Oxford University Press (OUP)

    Prof. Antonio Tursi

  41. Prognostic performance of the ‘DICA’ endoscopic classification and the ‘CODA’ score in predicting clinical outcomes of diverticular disease: an international, multicentre, prospective cohort study

    Article • Gut, October 2021, BMJ

    Prof. Antonio Tursi

  42. Prevalence of gastro-esophageal reflux disease in suspected laryngo-pharingeal reflux unresponsive to proton-pump inhibitors

    Article • Reviews on Recent Clinical Trials, August 2021, Bentham Science Publishers

    Prof. Antonio Tursi

  43. Effectiveness and Safety of A Nutraceutical Formulation for the Treatment of Functional Dyspepsia in Primary Care

    Article • Reviews on Recent Clinical Trials, July 2021, Bentham Science Publishers

    Prof. Antonio Tursi, Professor Ludovico Abenavoli, Antonio Pio Palieri, Federica Greco

  44. Letter: ustekinumab for the treatment of post‐surgical and refractory Crohn's disease

    Article • Alimentary Pharmacology & Therapeutics, March 2021, Wiley

    Prof. Antonio Tursi

  45. INTESTINAL MICROBIOME MODULATION DURING COVID-19: ANOTHER CHANCE TO MANAGE THE DISEASE?

    Article • Gastroenterology, September 2020, Elsevier

    Prof. Antonio Tursi

  46. Anti-TNF-α Agents in Inflammatory Bowel Disease and Course of COVID-19

    Article • Inflammatory Bowel Diseases, May 2020, Oxford University Press (OUP)

    Prof. Antonio Tursi

  47. COVID-19 infection in Crohn’s disease under treatment with adalimumab

    Article • Gut, April 2020, BMJ

    Prof. Antonio Tursi

  48. Covid-19 and the management of patients with inflammatory bowel disease: a practical decalogue for the post-pandemic phase

    Article • Therapeutic Advances in Gastroenterology, January 2020, SAGE Publications

    Prof. Antonio Tursi

  49. Complicated diverticulitis mimicking colonic carcinoma: combined approach with endoscopy and budesonide

    Article • BMJ Case Reports, December 2019, BMJ

    Prof. Antonio Tursi

  50. Vedolizumab is effective and safe in real-life treatment of inflammatory bowel diseases outpatients: A multicenter, observational study in primary inflammatory bowel disease centers

    Article • European Journal of Internal Medicine, August 2019, Elsevier

    Prof. Antonio Tursi

  51. Role of Inflammation in the Pathogenesis of Diverticular Disease

    Article • Mediators of Inflammation, March 2019, Hindawi Publishing Corporation

    Prof. Antonio Tursi

  52. Long-term efficacy of rifaximin to manage the symptomatic uncomplicated diverticular disease of the colon

    Article • Journal of Investigative Medicine, December 2018, BMJ

    Prof. Antonio Tursi

  53. Urinary metabolic profiling and symptomatic uncomplicated diverticular disease of the colon

    Article • Clinics and Research in Hepatology and Gastroenterology, June 2017, Elsevier

    Prof. Antonio Tursi

  54. Rectal Dieulafoy lesion

    Article • Clinics and Research in Hepatology and Gastroenterology, February 2017, Elsevier

    Prof. Antonio Tursi

  55. Effectiveness of golimumab in inducing remission and clinical response in outpatient ulcerative colitis

    Article • Clinics and Research in Hepatology and Gastroenterology, November 2016, Elsevier

    Prof. Antonio Tursi

  56. Diverticulosis today: unfashionable and still under-researched

    Article • Therapeutic Advances in Gastroenterology, December 2015, SAGE Publications

    Prof. Antonio Tursi

  57. Managing ambulatory ulcerative colitis patients with infliximab: A long-term follow-up study in primary gastroenterology centers

    Article • European Journal of Internal Medicine, October 2014, Elsevier

    Prof. Antonio Tursi

  58. Efficacy, safety, and applicability of outpatient treatment for diverticulitis

    Article • Drug Healthcare and Patient Safety, March 2014, Taylor & Francis

    Prof. Antonio Tursi

  59. Colonoscopy by nurse endoscopists: the right answer for the growing demand for colonoscopy in clinical practice?

    Article • Endoscopy, April 2013, Thieme Publishing Group

    Prof. Antonio Tursi